These are the top picks of Causeway Capital Management's Sarah Ketterer and Needham Funds' Chris Retzler.
Donald Trump is likely to go after a short list of drug companies in his vow to bring prices down, says Jake Novak.
The pharmaceutical company wins its hepatitis C drug trial against Gilead Sciences.
Some of the names on the move ahead of the open.
Merck was awarded $2.54 billion in royalties by a jury in a patent lawsuit against Gilead Sciences over Gilead's hepatitis C drugs.
These are the stocks posting the largest moves after the bell, including Oracle, Agio Pharmaceuticals, Adobe and more.
Shares of Gilead sink after-hours following a court order to pay Merck $2.5 billion in Hepatitis C royalties. CNBC's Meg Tirrell reports. The "Fast Money" traders weigh in.
While the markets are mostly lower following the Fed's rate hike decision, the Nasdaq biotech ETF IBB holds gains. CNBC's Jackie DeAngelis reports.
"Fast Money Halftime Report" traders Jon and Pete Najarian discusses unusual options activity in KeyCorp and Gilead.
Jim Cramer explains the relationship between Apple and the Federal Reserve, and why it could benefit from a rate hike.
Jim Cramer quickly gave his opinion on stocks from callers, including these at risk from the President-elect.
Jim Cramer explains why the Trump rally could be facing a roadblock after recent moves by the President-Elect.
Chris Retzler, Needham Growth Fund, and Ronny Gal, Sanford C. Bernstein, discuss buying opportunities amid health care's underperformance. With CNBC's Mike Santoli and Stephanie Link, TIAA Global Asset Management.
Ana Gupte, Leerink Partners, and Leonard Yaffe, StocDoc Partners, discuss stocks poised to win amid Trump's healthcare reform.
Jim Cramer gives his opinion on various stocks from callers at lightning speed.
Jim Cramer found the unexpected stocks behind the rally, pushing the market to all-time highs.
Pharmaceutical companies don't expect President-elect Donald Trump to continue the tough rhetoric on drug prices.
One anti-anxiety drug, Ativan, had an average unit cost increase of a stunning 1,264 percent between 2014 and 2015 for Medicaid.
Les Funtleyder, ESquare portfolio manager, shares his take on the healthcare sector amid a Trump presidency.
Jim Cramer gives his opinion in the Lightning Round, including one retailer that could gain strength out of the election.